Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4xCD3) ImmTAC targeting MAGE-A4 in solid tumors
A new T cell therapy shows promise against multiple solid tumors by redirecting immune cells to target a hidden cancer protein.
This Phase 1/2 trial reports the first-in-human evaluation of IMC-C103C, a bispecific ImmTAC molecule that redirects T cells against MAGE-A4-positive cancer cells in HLA-A*02:01-positive patients with advanced solid tumors. The trial establishes proof-of-concept for T cell receptor-based immunotherapy targeting an intracellular cancer-testis antigen, with activity observed across multiple tumor types.
What the study was
- Study design
- Phase 1/2 Clinical Trial (first-in-human dose escalation and expansion)
- Population
- Adult patients with advanced HLA-A*02:01-positive solid tumors expressing MAGE-A4
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Journal for immunotherapy of cancer
Why it surfaced
First-in-human Phase 1/2 of a novel ImmTAC bispecific (MAGE-A4xCD3) in refractory solid tumors; addresses major unmet need with a first-in-class mechanism targeting intracellular cancer-testis antigen.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.